Clinical trials: Hyperphosphatemia
Hyperphosphatemia
Bioequivalence Study of BAY77-1931 Granule
The study is conducted as a randomized, non-blinded, 2-way crossover study. Target population is 60 Japanese healthy male adult subjects selected by screening examination which will be conducted within 4 weeks before the first…
- Trial name
- NCT01053676
- Testing
- Lanthanum Carbonate (Fosrenol, BAY77-1931) Granule, Lanthanum Carbonate (Fosrenol, BAY77-1931) Chewable tablet
- Where
- Japan
- Volunteers
- 59 people, healthy volunteers welcome
- Sponsor
- Bayer
Kidney Failure, Chronic, Hyperphosphatemia
Pragmatic Randomised Trial of High Or Standard PHosphAte Targets in End-stage Kidney Disease (PHOSPHATE)
During end-stage kidney disease, clinical guidelines suggest reducing elevated phosphate levels in the blood. However, the effect of lowering blood phosphate levels on important patient-centred outcomes has never been tested.
- Trial name
- PHOSPHATE (NCT03573089)
- Testing
- Liberal phosphate target, Intensive phosphate target
- Where
- 126 sites in Australia, Brazil and 7 more
- Volunteers
- 3,600 people
- Sponsor
- The University of Queensland
Renal Dialysis, Hyperphosphatemia
Decreasing Intakes & Absorption of Phosphorus in Haemodialysis Patients Through Food Choices
Based on new evidence renal dietitians in Ireland are revising the diet sheet that is used to teach patients about reducing blood phosphate.
- Conditions
- Renal Dialysis, Hyperphosphatemia, Dietary Modification
- Trial name
- DIP HD (NCT03146923)
- Testing
- Current Low Phosphorus Diet Prescription, Modified Low Phosphorus Diet Prescription
- Where
- 10 sites in Ireland
- Volunteers
- 74 people
- Sponsor
- University College Cork
Chronic Renal Failure Patients With Hyperphosphataemia Receiving Hemodialysis
Post-marketing Surveillance of Kiklin Capsules in Hemodialysis Patients
The purpose of this survey is to evaluate the safety and efficacy of long-term use of Kiklin® Capsules in actual clinical settings.
- Trial name
- NCT01901107
- Testing
- Kiklin capsules
- Where
- 8 sites in Japan
- Volunteers
- 1,078 people
- Sponsor
- Astellas Pharma Inc
Chronic Kidney Disease
Optimal Titration Regimen for SBR759 in Lowering Serum Phosphate Levels in Asian Chronic Kidney Disease Patients on Hemodialysis
This study will determine the titration regimen for SBR759 compared to sevelamer HCl in lowering serum phosphate levels in Asian Chronic Kidney Disease patients on hemodialysis
- Trial name
- SBR759 (NCT00704678)
- Testing
- SBR759, Sevelamer HCl
- Where
- 15 sites in Japan, Taiwan
- Volunteers
- 203 people
- Sponsor
- Novartis Pharmaceuticals
Hyperphosphatemia
BAY 77-1931 Long-term Extension From Phase II Study
A long-term study of BAY77-1931 (lanthanum carbonate) for hyperphosphatemia in patients undergoing hemodialysis
- Trial name
- NCT00769496
- Testing
- BAY 77-1931
- Where
- 14 sites in Japan
- Volunteers
- 145 people
- Sponsor
- Bayer
End Stage Renal Disease, Hyperphosphatemia
A Study of Ferric Citrate to Improve Inflammation and Lipid Levels
The risk of cardiovascular mortality in patients with end stage renal disease on hemodialysis is 10-100 times higher than the normal population.
- Conditions
- End Stage Renal Disease, Hyperphosphatemia, Chronic Inflammation
- Trial name
- NCT02661295
- Testing
- Ferric Citrate
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Winthrop University Hospital
Hyperphosphatemia
Post Marketing Surveillance Study to Observe Safety and Effectiveness of NEPHOXIL ® in S. Korea Patients
The objective of this post-marketing surveillance (PMS) study is to assess the safety and effectiveness of Nephoxil capsule 500 mg (Ferric Citrate 500 mg, equivalent to 105 mg Ferric Iron) in routine clinical settings
- Trial name
- NCT06186934
- Testing
- the standard-dose group (4 g/day)
- Where
- South Korea
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Kyowa Kirin Korea Co., Ltd.
Hyperphosphatemia
Clinical Study of KHK7791 in Hyperphosphatemia Patients on Hemodialysis
To evaluate the efficacy of KHK7791 by comparing changes in serum phosphorus levels from baseline values between hemodialysis patients with hyperphosphatemia receiving repeated administration of KHK7791 for 8 weeks and those…
- Trial name
- NCT04767581
- Testing
- KHK7791
- Where
- Japan
- Volunteers
- 165 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Chronic Kidney Disease Requiring Chronic Dialysis
A Phase 3 Study to Investigate the Safety and Efficacy of PA21, a Phosphate Binder, in Dialysis Patients
This is a Phase 3, randomised, active controlled, multicentre study to investigate the safety and efficacy of PA21, a phosphate binder, for control of hyperphosphataemia in dialysis patients.
- Trial name
- NCT01324128
- Testing
- PA21 (2.5 g tablet containing 500 mg iron), Sevelamer carbonate, PA21-1 (1.25 g tablet containing 250 mg iron)
- Where
- 15 sites in United States, Austria and 13 more
- Volunteers
- 1,059 people
- Sponsor
- Vifor Pharma
Hyperphosphatemia, Chronic Kidney Disease
Drug-Drug Interaction Study to Evaluate the Effect of Colestilan on the Pharmacokinetics of Single Doses of Candesartan Cilexetil in Healthy Subjects
The primary objective is to assess the effects of colestilan on the pharmacokinetic profile of candesartan cilexetil when administered at the same time as, 1 hour before, and 3 hours after the first daily dose of colestilan…
- Trial name
- NCT01976572
- Testing
- colestilan, candesartan
- Where
- United Kingdom
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Tanabe Pharma Corporation
Metabolic Bone Disease
The Effect of Lanthanum Carbonate on Fibroblast Growth Factor 23 ( FGF23) in Chronic Kidney Disease
The aim of the study is to assess the effects of the drug lanthanum carbonate (a phosphorus binder drug) on c-terminal and on FGF23 levels in patients with Chronic Kidney Disease (CKD).
- Trial name
- NCT01002872
- Testing
- Lanthanum Carbonate (Fosrenol)
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Endeavor Health
Chronic Kidney Disease, Renal Insufficiency
Long-term Study in Chronic Kidney Disease Patients With Hyperphosphatemia Not on Dialysis
This is a multi-center, open-labeled, non-comparative study to examine the safety and efficacy of ASP1585 for long-term dosing in chronic kidney disease patients with hyperphosphatemia not on dialysis.
- Conditions
- Chronic Kidney Disease, Renal Insufficiency, Hyperphosphatemia
- Trial name
- NCT01742611
- Testing
- ASP1585
- Where
- 5 sites in Japan
- Volunteers
- 105 people
- Sponsor
- Astellas Pharma Inc
Hyperphosphatemia
Evaluation of Renvela in Patients With Chronic Kidney Disease Not On Dialysis And Hyperphosphatemia In China
Primary Objective: To demonstrate efficacy of Renvela tablets in the reduction of serum phosphorus in hyperphosphatemia in participants with chronic kidney disease not on dialysis.
- Trial name
- RECOVER (NCT03001011)
- Testing
- Sevelamer Carbonate (GZ419831)
- Where
- 38 sites in China
- Volunteers
- 202 people
- Sponsor
- Sanofi
Hyperphosphataemia
Study to Evaluate the Efficacy and Safety of PT20 in Subjects With Hyperphosphataemia and Dialysis Dependent Chronic Kidney Disease
The main purpose of this study is to see whether PT20 can help people with a high level of phosphate in their blood (called Hyperphosphatemia) that are being treated with dialysis for kidney disease.
- Trial name
- NCT02151643
- Testing
- PT20
- Volunteers
- 153 people
- Sponsor
- Phosphate Therapeutics
Hyperphosphatemia
Long-term Effect of Lanthanum Carbonate on Bone
Patients enrolled in a previous study (SPD405-309), who were exposed to lanthanum carbonate (Fosrenol), were eligible to continue on any prescribed treatment for hyperphosphatemia, including lanthanum carbonate (Fosrenol), for an…
- Trial name
- NCT00557323
- Testing
- Lanthanum carbonate
- Where
- 19 sites in United States, Germany and 1 more
- Volunteers
- 34 people
- Sponsor
- Shire
Hyperphosphatemia
An 8-Week Study to Evaluate Tenapanor in the Treatment of Hyperphosphatemia in End-Stage Renal Disease Patients on Hemodialysis (ESRD-HD)
This phase 3, 8-week, randomized, double-blind, parallel group, multi-center study with a 4-week, placebo-controlled, randomized withdrawal period will evaluate the efficacy, safety and tolerability of Tenapanor to treat…
- Trial name
- NCT02675998
- Testing
- Tenapanor
- Where
- 32 sites in United States
- Volunteers
- 219 people
- Sponsor
- Ardelyx
Hyperphosphatemia
Dose Finding Study to Treat High Phosphate Levels in the Blood.
Randomized. double blind, placebo controlled, parallel arms dose finding study with a 4 weeks treatment period
- Trial name
- NCT02081534
- Testing
- AZD1722
- Where
- 41 sites in United States, Poland and 2 more
- Volunteers
- 162 people
- Sponsor
- Ardelyx
Hyperphosphataemia, ESRD
Non-interventional Study to Evaluate the Ease of Reaching Individual Goals in Serum Phosphorus (Steering)
The objective of this non-interventional study is to confirm that with standard OsvaRen® treatment it is possible to achieve in at least 60% of the patients the levels of phosphorus, total calcium, and iPTH seen in the CALMAG…
- Trial name
- Steering (NCT01424787)
- Where
- 24 sites in Denmark, Germany and 2 more
- Volunteers
- 324 people
- Sponsor
- Fresenius Medical Care Deutschland GmbH
Phosphate Deficiency, Phosphate Overload
Institution of an Italian Multicenter Database of Patients Affected by Diseases of Phosphate Metabolism
The goal of this observational study is to create, manage and analyze a multicenter national database of patients affected by diseases of phosphate metabolism, aimed at collecting and studying anamnestic, diagnostic, genetic…
- Trial name
- NCT06826664
- Where
- 28 sites in Italy
- Volunteers
- 100 people
- Sponsor
- F.I.R.M.O. - Fondazione Italiana Ricerca sulle Malattie dell'Osso - Ente del Terzo Settore